Literature DB >> 10952622

Use of saliva specimens for monitoring indinavir therapy in human immunodeficiency virus-infected patients.

U Wintergerst1, M Kurowski, B Rolinski, M Müller, E Wolf, H Jaeger, B H Belohradsky.   

Abstract

Indinavir concentrations were determined in plasma and saliva over a random period of 4 h. On average, levels in saliva were 70% +/- 38% of the corresponding levels in plasma. These findings suggest that saliva might serve as an appropriate specimen for monitoring of plasma indinavir levels in patients treated with indinavir.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952622      PMCID： PMC90112          DOI： 10.1128/AAC.44.9.2572-2574.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Indinavir concentrations and antiviral effect.

Authors:  E P Acosta; K Henry; L Baken; L M Page; C V Fletcher
Journal:  Pharmacotherapy       Date:  1999-06       Impact factor: 4.705

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

Authors:  R L Murphy; J P Sommadossi; M Lamson; D B Hall; M Myers; A Dusek
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

5.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

6.  Single-dose pharmacokinetics of indinavir and the effect of food.

Authors:  K C Yeh; P J Deutsch; H Haddix; M Hesney; V Hoagland; W D Ju; S J Justice; B Osborne; A T Sterrett; J A Stone; E Woolf; S Waldman
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  Monitoring theophylline therapy using citric acid-stimulated saliva in infants and children with asthma.

Authors:  M Aviram; A Tal; Z Ben-Zvi; R Gorodischer
Journal:  Pediatrics       Date:  1987-12       Impact factor: 7.124

8.  Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients.

Authors:  B Rolinski; U Wintergerst; A Matuschke; H Füessl; F D Goebel; A A Roscher; B H Belohradsky
Journal:  AIDS       Date:  1991-07       Impact factor: 4.177

9.  Salivary phenytoin concentrations in epilepsy and in chronic renal failure.

Authors:  F Reynolds; P N Ziroyanis; N F Jones; S E Smith
Journal:  Lancet       Date:  1976-08-21       Impact factor: 79.321

10.  Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

Authors:  R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; L Jonas; A Meibohm; D Holder; W A Schleif; J H Condra; E A Emini; R Isaacs; J A Chodakewitz; D D Richman
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272
View more
  2 in total

Review 1.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

2.  Supporting children to adhere to anti-retroviral therapy in urban Malawi: multi method insights.

Authors:  Ralf Weigel; Ireen Makwiza; Jean Nyirenda; Darles Chiunguzeni; Sam Phiri; Sally Theobald
Journal:  BMC Pediatr       Date:  2009-07-14       Impact factor: 2.125
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.